[go: up one dir, main page]

NO950134L - Formuleringer for oralt administrerte farmasöytiske midler - Google Patents

Formuleringer for oralt administrerte farmasöytiske midler

Info

Publication number
NO950134L
NO950134L NO950134A NO950134A NO950134L NO 950134 L NO950134 L NO 950134L NO 950134 A NO950134 A NO 950134A NO 950134 A NO950134 A NO 950134A NO 950134 L NO950134 L NO 950134L
Authority
NO
Norway
Prior art keywords
formulations
orally administered
pharmaceutical agents
administered pharmaceutical
compound
Prior art date
Application number
NO950134A
Other languages
English (en)
Other versions
NO950134D0 (no
Inventor
Stephanie Ann Sweetana
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO950134D0 publication Critical patent/NO950134D0/no
Publication of NO950134L publication Critical patent/NO950134L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det blir beskrevet nye formuleringer for levering av farmasøytiske forbindelser ved oral administrasjon, som muliggjør betydelig biotllgjengelighet av den aktive Ingrediensen l formuleringen. Disse formuleringene omfatter en farmasøytisk forbindelse som er hoved- sakelig uoppløsellg i vann. Forbindelsen blir oppløst i en bærer som omfatter en langkjedet fri fettsyre som oppløselighetsmlddel, en farmasøytisk akseptabel olje og et overflateaktlvt middel. Ved denne formuleringen blir opplesellgheten av den farmasøytiske forbindelsen øket, og derved blir den systemiske leveringen for- bedret.
NO950134A 1994-03-01 1995-01-13 Formuleringer for oralt administrerte farmasöytiske midler NO950134L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20342494A 1994-03-01 1994-03-01

Publications (2)

Publication Number Publication Date
NO950134D0 NO950134D0 (no) 1995-01-13
NO950134L true NO950134L (no) 1995-09-04

Family

ID=22753951

Family Applications (1)

Application Number Title Priority Date Filing Date
NO950134A NO950134L (no) 1994-03-01 1995-01-13 Formuleringer for oralt administrerte farmasöytiske midler

Country Status (15)

Country Link
EP (1) EP0670166A3 (no)
JP (1) JPH0840936A (no)
KR (1) KR950031039A (no)
CN (1) CN1114588A (no)
AU (1) AU1354495A (no)
BR (1) BR9500754A (no)
CA (1) CA2138607A1 (no)
CZ (1) CZ51995A3 (no)
HU (1) HUT75252A (no)
IL (1) IL112745A0 (no)
NO (1) NO950134L (no)
NZ (1) NZ270145A (no)
PE (1) PE10396A1 (no)
PL (1) PL307469A1 (no)
ZA (1) ZA95936B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9705813D0 (en) * 1997-03-20 1997-05-07 Smithkline Beecham Plc Novel compositions
WO2000040220A1 (en) * 1999-01-06 2000-07-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
KR100435141B1 (ko) * 2000-12-28 2004-06-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
EA201100152A1 (ru) * 2008-11-20 2011-12-30 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Лекарственные формы производного пиразолона
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US8591942B2 (en) 2009-09-23 2013-11-26 Indu JAVERI Methods for the preparation of liposomes comprising docetaxel
WO2018102345A1 (en) * 2016-11-30 2018-06-07 Agrobiologics Llc Use of the antifungal aureobasidin a in agriculture
AU2018313933B2 (en) * 2017-08-09 2024-03-07 Dechra Veterinary Products, Llc Therapeutic formulations and uses thereof
EP3972582A4 (en) * 2019-05-20 2023-10-04 Poviva Corp. COMPOSITIONS MTI BIOLOGICAL ACTIVE INGREDIENTS AND BILE SALTS
CN119837902B (zh) * 2025-01-15 2025-10-17 成都世联康健生物科技有限公司 一种抗菌颊部贴片及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
JPH04305534A (ja) * 1991-04-02 1992-10-28 Takara Shuzo Co Ltd オーレオバシジン類製剤
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
JPH0672890A (ja) * 1992-06-26 1994-03-15 Nippon Kayaku Co Ltd オーレオバシジン類の乳化製剤

Also Published As

Publication number Publication date
ZA95936B (en) 1995-10-09
CA2138607A1 (en) 1995-09-02
CN1114588A (zh) 1996-01-10
HU9500618D0 (en) 1995-04-28
EP0670166A3 (en) 1996-06-12
IL112745A0 (en) 1995-05-26
KR950031039A (ko) 1995-12-18
PL307469A1 (en) 1995-09-04
EP0670166A2 (en) 1995-09-06
PE10396A1 (es) 1996-04-11
NO950134D0 (no) 1995-01-13
JPH0840936A (ja) 1996-02-13
BR9500754A (pt) 1995-10-24
NZ270145A (en) 1996-08-27
CZ51995A3 (en) 1995-10-18
HUT75252A (en) 1997-05-28
AU1354495A (en) 1995-09-07

Similar Documents

Publication Publication Date Title
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
AR018829A1 (es) Formulaciones farmaceuticas solidas de rapida desintegracion, administrables via oral y procedimiento para prepararlos
NO20014718D0 (no) Formulering inneholdende testosteron-undekanoat og castorolje
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
EP0287341B1 (en) Rectally absorbable form of l-dopa
CA2382886A1 (en) Benzamide formulation with histone deacetylase inhibitor activity
EA200000154A1 (ru) Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях
NO961136L (no) Farmasöytisk formuleringsgrunnlag for nano-suspensjoner
MY100721A (en) Therapeutic agent.
CY1112510T1 (el) Φαρμακευτικο παρασκευασμα υπο τη μορφη παστας το οποιο περιεχει ενα ασταθες στα οξεα δραστικο συστατικο
CO5560580A2 (es) Formulaciones de sucralosa para disumular sabores desagradables
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
ES2238393T3 (es) Composiciones farmaceuticas conteniendo mupirocina en forma amorfa.
CA2215327A1 (en) Formulations for lipophilic compounds
CA2231342A1 (fr) Composition pharmaceutique pour administration par voie orale
US4888343A (en) Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
ES2149990T3 (es) Composiciones farmaceuticas solidas que contienen ingrediente activo de acido (s)-2-(4-isobutilfenil)propionico y celulosa microcristalina y silice coloidal como excipientes.
TNSN97134A1 (fr) Comprime de maleate de trimebutine pellicule
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
MY129450A (en) Pharmaceutical composition
IL92799A0 (en) Benzimidazole derivatives with gastric acid inhibition and process for its preparation
HUP9901887A2 (hu) HIV-proteáz inhibitort és vízoldékony E-vitamin származékokat tartalmazó gyógyászati készítmények